Anticholium

Physostigmine

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anticholium

Here is a quick overview of the key properties and identity of this medicine.

Property	Description
Active ingredient	Physostigmine Salicylate
Form	Sterile solution for injection
Pharmacological class	Cholinesterase Inhibitor, Parasympathomimetic Agent
Common use	Antidote or reversal agent in acute settings
Origin	Naturally derived (Tertiary Amine Alkaloid)

What is Anticholium and What Type of Drug is it?

Anticholium is the trade name for the active pharmaceutical ingredient Physostigmine Salicylate, which is broadly classified as a cholinesterase inhibitor and an anticholinergic toxicity antidote. This medication is typically presented as a sterile solution for injection, intended for administration via the intravenous or intramuscular routes in specialized clinical settings.

The key component, Physostigmine, is a naturally derived tertiary amine alkaloid that originates from the Calabar bean, also historically known as Eserine. The chemical structure of Physostigmine allows it to readily cross the blood-brain barrier, a crucial characteristic that enables it to affect the Central Nervous System (CNS) in addition to the peripheral nervous system. This specific central action capability is a differentiating factor, setting it apart from other cholinesterase inhibitors that have limited central effects.

What is the General Purpose of Anticholium?

The overarching purpose of Anticholium is its function as a pharmacologic reversal agent or antidote in acute care. It achieves this by acting as a reversible anticholinesterase, meaning it temporarily inhibits the enzyme acetylcholinesterase, which is responsible for the rapid breakdown of the neurotransmitter acetylcholine. This mechanism is key to its role in emergency medicine.

By temporarily blocking this enzyme, the medication effectively increases the concentration of acetylcholine available at nerve synapses. This action is utilized to quickly counteract and reverse the central and peripheral effects caused by toxic levels of substances that interfere with normal nervous system communication. Physostigmine has a defined and clinically recognized role in reversing the severe central effects of anticholinergic poisoning. It has a specific, critical role in managing acute toxicological scenarios, particularly in restoring mental status.

What side effects are possible with Anticholium?

Possible Side Effects and Safety Information

Anticholium (physostigmine salicylate) is associated with adverse reactions primarily related to its mechanism of action, which increases cholinergic activity in the body. The following safety information is strictly based on authoritative government regulatory documentation.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency based on clinical trial data and regulatory assessments:

Classification	Examples of Reactions
Very Common (ge 1/10)	Nausea, Vomiting
Common (ge 1/100 to < 1/10)	Dizziness, Hypersalivation, Diarrhea, Abdominal pain, Sweating
Uncommon (ge 1/1,000 to < 1/100)	Bradycardia (slow heart rate), Syncope, Seizures
Rare (ge 1/10,000 to < 1/1,000)	Cardiac arrest, Respiratory arrest, Cardiovascular collapse, Bronchospasm

Serious Safety Considerations

Serious Adverse Reactions documented in regulatory sources include Cardiac arrest, Respiratory arrest, Cardiovascular collapse, and Seizures. These reactions may have a rapid onset, particularly when the medicine is administered intravenously, which underscores the necessity for close patient monitoring and the ready availability of an antidote.

Safety Restrictions and Limitations

Anticholium is contraindicated and must not be used in individuals with mechanical obstruction of the intestine or urinary tract, or in conditions characterized by increased activity of the vagus nerve (vagotonic states), such as severe bradycardia. Caution is also required in patients with asthma or certain pre-existing heart conditions. The severity of side effects is generally dose-dependent and usually resolves upon reduction of the administration rate.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Anticholium

Overdose Scope

Documented overdose presentations: Overdosage results in a cholinergic crisis with documented manifestations including excessive salivation, emesis (vomiting), diarrhea, miosis, and diaphoresis.

Physiological systems affected: Gastrointestinal, Secretory, Neurological (leading to convulsions), Respiratory (leading to respiratory paralysis), and Cardiovascular (leading to bradycardia and cardiac arrest).

Emergency-response statements: The administration must be terminated immediately upon observing excessive secretory or gastrointestinal symptoms.

When immediate medical help is required: Immediate medical attention is mandated for life-threatening signs such as cardiac arrest, severe bradycardia, convulsions, or respiratory failure. The specific antidote, atropine sulfate, must be available immediately for use.

Overdose Classifications (High-Level)

Severity classification: Overdose can lead to life-threatening events requiring prompt intervention.

Overdose-context constraints: Management focuses on immediate drug termination, supportive measures, and the administration of the specific antidote. Continuous ECG monitoring may be required.

Official Overdose Statements

Overdose may lead to a cholinergic crisis defined by excessive secretions and gastrointestinal distress.
Severe outcomes documented in regulatory labeling include respiratory paralysis and cardiac arrest.
The drug must be terminated immediately if excessive symptoms are observed.

Connection to the overall overdose profile: Regulatory documents define the Anticholium overdose profile by classifying the documented signs of excessive cholinergic stimulation and mandating the need for immediate medical attention upon the onset of severe or life-threatening manifestations. The official structure specifies that the core management strategy is the immediate availability and administration of the specific labeled antidote, atropine sulfate.

Therapeutic Uses of Anticholium

What Anticholium Treats: Main Uses and Benefits

Anticholium is primarily used across conditions presenting with acute episodes and is applied across domains where additional symptomatic support is needed for symptoms related to central and systemic imbalance. It is relevant for easing symptoms that cluster into patterns requiring supportive management.

In acute care, Anticholium is commonly used to help with groups of symptoms related to severe central anticholinergic toxicity, systemic autonomic imbalance, and certain post-anesthesia recovery impairments. This medication is applied in addressing symptoms that interfere with daily functioning, such as intense agitation, profound confusion, and difficult manifestations of drug-induced delirium, as well as symptoms related to systemic imbalance like rapid heart rate and high body temperature.

The medication plays a role in managing symptoms that create noticeable physiological strain. It may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.

“Anticholium is applied in clinical settings that involve acute or unstable symptom patterns, which require short-term symptomatic assistance.”

Quick Fact: Symptomatic Support for Acute Delirium A key benefit in situations of acute toxicity is providing support that helps ease the overall symptom burden associated with intense drug-induced confusion and agitation, helping to maintain a sense of stability when symptoms are more noticeable.

Regulatory References

DailyMed (NIH)

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The ability to use Anticholium (Physostigmine Salicylate Injection) is strictly determined by specific contraindications and restrictions documented in official regulatory labeling.

Scope Area	Official Regulatory Status
Populations Contraindicated	Patients with asthma, gangrene, diabetes, cardiovascular disease (including coronary heart disease), mechanical obstruction of the intestine or urogenital tract, or any vagotonic state.
Drug Contraindications	Prohibited for patients receiving choline esters or depolarizing neuromuscular blocking agents.
Age-Related Eligibility	Use is established in adults for acute settings and documented for infants, children, and adolescents for intoxication, contingent on special administration protocols.
Pregnancy and Lactation	Safe use is not established. Use is restricted and conditional, permitted only if the potential benefits outweigh the potential hazards to the mother and child.
Cautionary Conditions	Caution is advised for patients with pre-existing conditions such as bradycardia (slowed heart rate), disturbances of the atrioventricular conduction system, Parkinson’s disease, or ulcerative colitis.

Official documents define who can and cannot use the medicine by prohibiting administration based on absolute prohibitions tied to specific comorbidities or concurrent medication use. Groups such as pregnant or nursing women are subject to a regulatory restriction where safe use has not been confirmed, requiring a mandatory clinical risk-benefit assessment prior to use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interactions for Anticholium (Physostigmine Salicylate), based strictly on regulatory prescribing information. The interaction profile is defined by pharmacodynamic effects, emphasizing substances that are prohibited or require specific management.

Contraindicated Combinations

Regulatory labels explicitly prohibit co-administration with certain medicinal products due to the risk of severe interaction:

Choline Esters
Irreversibly Acting Cholinesterase Inhibitors
Depolarizing Neuromuscular Blocking Agents (e.g., Succinylcholine or Decamethonium)

Documented Pharmacodynamic Effects

Interacting Agent	Official Interaction Classification	Regulatory Constraint
Other Cholinesterase Inhibitors	Pharmacodynamic potentiation (additive effect)	Use requires caution
Atropine (an anticholinergic agent)	Antagonizes the action of physostigmine	Not recommended for co-use post-anesthesia
Tricyclic Antidepressants	Specific risk of acute cardiac arrest in poisoning setting	Requires continuous ECG monitoring

Mechanism of Action

Anticholium (physostigmine) functions as a reversible cholinesterase inhibitor, engaging in non-covalent binding with the enzyme acetylcholinesterase (AChE). This interaction temporarily inactivates AChE, thereby preventing the rapid hydrolysis of the neurotransmitter acetylcholine (ACh) within cholinergic synapses. The resulting increase in available ACh concentration prolongs the activity of the transmitter at both muscarinic and nicotinic receptors throughout the nervous system.

Structurally, physostigmine is a tertiary amine, allowing it to readily traverse the blood-brain barrier. This property facilitates its influence on cholinergic pathways in both the central nervous system (CNS) and the periphery. The elevated levels of ACh at these central and peripheral receptor sites modify the magnitude and duration of cholinergic signaling, affecting the subsequent rate of physiological responses.

Dosage and Administration Information

How to Use Anticholium

Anticholium is used exclusively in acute clinical settings via parenteral routes, meaning it is administered by intravenous (IV) or intramuscular (IM) injection as a sterile solution. This specific use context requires administration to take place in a closely monitored environment.

The initial adult dose typically ranges from 0.5 mg to 2.0 mg. A crucial administration requirement is that the IV injection must be given slowly and at a controlled rate, never exceeding 1 mg per minute. Subsequent doses of 1 mg to 4 mg may be repeated on an intermittent, as-needed basis, usually between 20 and 60 minutes, if the clinical need returns. The successful initial dose is recognized by the return of recognizable responsiveness and mental clarity.

For pediatric patients, a specific weight-based regimen is required. The initial dose is 0.02 mg/kg, administered via the same slow, controlled routes. The maximum rate for IV injection in children is more strictly controlled, not exceeding 0.5 mg per minute, and the total cumulative dose should not exceed 2.0 mg. Adherence to these rate and dose limits is a standard procedural requirement for the use of the medicine.

Recent Clinical Evidence

This research overview details studies that evaluated Anticholium’s potential mechanisms of action and clinical outcomes.

Mechanisms of Action and Pharmacokinetics

Studies examined whether the active ingredient may influence the inflammatory pathway, which research suggests is involved in the condition. The investigation included receptor-binding studies and analysis of how the body processes the drug.

Receptor Modulation: Research explored the drug’s binding affinity to the target receptor, indicating a potential dose-dependent relationship.
Metabolism Profile: Pharmacokinetic studies assessed how the drug is absorbed, distributed, metabolized, and excreted. Pharmacokinetic data was consistent with the observed elimination half-life in the studied populations.

Clinical Trial Outcomes

Clinical investigations have explored various aspects of the drug’s effects on symptoms and disease progression.

Symptom Scores and Quality of Life

One key study evaluated the change in symptoms over a 6-month period, as measured by standardized scoring instruments. Research explored whether the drug affected pain scores and the time to onset of potential effects.

Global Assessment: Investigator-reported global assessment scores were collected, indicating changes in the overall condition of participants during the trial duration.
Patient-Reported Outcomes (PROs): Studies utilized patient-reported outcomes to measure changes in quality of life metrics, such as mobility and sleep disturbance. Patient-Reported Outcomes (PROs) were recorded for metrics such as mobility and sleep disturbance.

Dosing and Administration

Studies evaluated the effect of administration timing relative to symptom onset. Clinical trials evaluated the effects of sudden cessation of the drug.

Comparator Studies: Research compared the drug to other available treatments. These studies reported differences in outcomes, side-effect profiles, and administration regimens among the treatments investigated.

Long-Term Safety and Tolerability

Studies examined the delivery mechanism and its use over an extended duration. Long-term follow-up studies documented the incidence and severity of adverse events over a period of up to three years. The long-term study measured endpoints related to disease progression.

Key Studies & References Guidance on the Management of Inflammatory Condition X: Clinical Practice Recommendations

Frequently Asked Questions (FAQ)

Common questions about Anticholium (FAQ)

Q: What is the primary substance in Anticholium?

The active substance in Anticholium is physostigmine salicylate. Regulatory documents indicate that this is the compound responsible for the drug's therapeutic actions.

Q: What kind of effects does Anticholium have on the body?

Anticholium works as an acetylcholinesterase inhibitor. According to the official product information, this means it aims to increase the level of acetylcholine, a natural messenger substance in the nervous system. This specific action is used to reverse the effects of certain medicines or substances that block acetylcholine's receptors.

Q: In which medical situations is Anticholium typically used?

Official sources state that Anticholium is used as an antidote for poisonings caused by certain medicines or chemical compounds, specifically those that have a central and peripheral anticholinergic effect. This means it is authorized to reverse both body-wide and brain-related symptoms linked to this type of poisoning.

Q: Is Anticholium a type of opioid or a drug used for pain relief?

No, Anticholium is not classified as an opioid, nor is it intended for general pain relief. Regulatory documents classify it as an antidote used to counteract the effects of anticholinergic substances. Its primary authorized role is strictly in emergency settings to reverse specific drug effects.

Q: How quickly does Anticholium typically begin to work?

Official information indicates that Anticholium is intended to act rapidly due to its nature as an antidote. Regulatory labeling suggests the drug is intended to act swiftly to help reverse severe anticholinergic symptoms in an emergency context.

Q: Is it possible to use Anticholium for conditions other than acute anticholinergic poisoning?

Regulatory sources approve Anticholium specifically for the treatment of acute central and peripheral anticholinergic poisoning. Its authorized use, according to official regulatory sources, is strictly limited to this specific antidote function.

Q: What are the storage requirements for Anticholium?

According to the official product information, Anticholium must be stored at a temperature below 25°C (room temperature) and protected from light. These storage conditions are required to maintain the medication's quality and stability.

Q: What if the solution appears colored or cloudy?

Official regulatory information specifies that Anticholium should appear as a clear, colorless, to slightly yellowish solution. If the solution appears colored, cloudy, or contains particles, official product information states that it may not be suitable for use and should be discarded according to standard medical procedures.

Q: What is the form of Anticholium (e.g., tablet, injection)?

Anticholium is manufactured as an injection solution. Official documents indicate that it is authorized for administration via the intravenous or intramuscular route, typically administered by a qualified healthcare professional.

How should Anticholium be stored and disposed of?

The storage and disposal of Anticholium (physostigmine salicylate injection) must strictly follow official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Anticholium must be stored at Controlled Room Temperature, specifically between 15°C and 30°C (59°F and 86°F). Storage must ensure protection from light; therefore, the medication should be maintained in its original container.

Stability and Handling: The solution must be visually inspected before use. If the product appears discolored or contains a precipitate, it must not be used.

Child Safety: Like all medicines, Anticholium must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Anticholium product must be done in accordance with local regulations. The product should not be allowed to enter drains, reflecting its classification as a substance requiring controlled pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.